Loading clinical trials...
Loading clinical trials...
Phase Ⅱ Clinical Trial of ssCART-19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Conditions
Interventions
ssCART-19
Fludarabine
+1 more
Locations
2
China
Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Soochow University
Suzhou, China
Start Date
April 1, 2024
Primary Completion Date
September 1, 2024
Completion Date
December 1, 2025
Last Updated
April 19, 2024
Lead Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions